© 2020 MJH Life Sciences and Urology Times. All rights reserved.
© 2020 MJH Life Sciences™ and Urology Times. All rights reserved.
August 14, 2020
Response and survival rates with the immunotherapy-based regimen support ongoing phase 3 research with pembrolizumab in prostate cancer.
August 05, 2020
Holmium laser lithotripsy with Moses 2.0 is intended to enhance precision and versatility by optimizing laser energy transmission.
July 30, 2020
A subgroup analysis of the pivotal phase 3 ARAMIS trial showed that the efficacy of darolutamide was sustained in patients with a rapid PSA double time.
Minimally invasive water vapor thermal therapy offers rapid improvements in LUTS, QoL, and flow rate that remain durable to 5 years in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
July 29, 2020
Super-pulsed thulium fiber laser (TFL) has greater efficiency than a holmium:YAG laser, even when using the TFL with a smaller core-diameter fiber, according to preclinical findings.
July 28, 2020
The machine learning algorithm incorporates readily available clinical information.
Mediterranean diet score was modestly associated with time to grade group progression.
July 27, 2020
“Our findings suggest that genomic score and PSA density are risk factors for upgrading within 3 years of commencing active surveillance,” the investigators wrote.
A study author said that “the long exposure [to immune checkpoint inhibitor therapy] results in challenging surgery.”
July 24, 2020
Intravesical Oncofid P-B, a conjugate of paclitaxel and hyaluronic acid, is active in patients with carcinoma in situ of the bladder that is not responsive to bacillus Calmette-Guérin.
Given the efficacy and safety demonstrated, there may be a role going forward for the pembrolizumab/nab-paclitaxel combination in earlier disease stages.
July 23, 2020
Treatment with litoxetine, an investigational oral selective serotonin reuptake inhibitor, led to nearly 22% of patients becoming continent.
Referring physicians implemented PSMA PET–based treatment changes in 72% of patients.
The study compared the 2 procedures over 24 months of follow-up.
July 22, 2020
Retreatment rates were low with both aquablation and transurethral resection of the prostate.
Cancers that are missed by mpMRI are significantly smaller and less aggressive than those that are detected.
July 21, 2020
In patients with prior exposure to PDE5 inhibitors, increasing the number of sessions of low-intensity shockwave therapy was associated with improving outcomes.
The EUPROMS patient-driven quality-of-life study included data from almost 3000 men treated for prostate cancer.
July 20, 2020
Steroid sulfatase inhibition showed early activity as a precision option in castrate-resistant prostate cancer, including the potential to enhance response to enzalutamide.